Law360 Names Cravath a 2023 “Mergers & Acquisitions Practice Group of the Year”
February 14, 2024
On February 12, 2024, Cravath was featured by Law360 as a “Mergers & Acquisitions Practice Group of the Year,” receiving the distinction for the eleventh time in thirteen years. The profile highlighted the Firm’s role representing the Snyder Family in its sale of the Washington Commanders to Josh Harris and partners, WestRock in its $20 billion combination with Smurfit Kappa, Brookfield Renewable in its and Cameco’s $7.875 billion acquisition of Westinghouse and Biogen in its $7.3 billion acquisition of Reata Pharmaceuticals.
Cravath partner Mark Greene, head of the Firm’s Corporate Department and leader of its International Practice, reflected on the factors that made the Firm’s work for the Snyder Family so complex, including the National Football League’s ownership rules which are among “the most rigorous … of the professional sports leagues in the U.S.” and the “high‑profile and very public” nature of the deal. Mark added that the complexity of the deal is precisely what made “for a very interesting and rewarding transaction.” Richard Hall, partner and head of the Firm’s M&A Practice for EMEA, spoke about the practice’s strengths, including its ability to navigate multijurisdictional regulatory requirements, and attributed this ability to “the experience that we have in transactions [that] allows us to identify upfront where issues might arise.” Partner Bethany A. Pfalzgraf praised the group’s approach to transactions involving biopharmaceutical companies: “it's really about creating a collaborative team with your client.”
Related Practices & Industries
People
- Photo
-
-
J.D., 1993, University of Pennsylvania Law School
-
B.A., 1989, Cornell University
- New York
Education
Admitted In
- Photo
-
-
LL.M., 1988, Harvard Law School
-
LL.B., 1986, University of Melbournewith Honors
-
B.Com., 1984, University of Melbournewith Honors
- New York
Education
Admitted In
- Photo
-
-
J.D., 2014, Columbia Law SchoolHarlan Fiske Stone Scholar
-
B.A., 2010, Boston CollegeCollege of Arts and Sciences Honors Program, cum laude
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
May 12, 2023
The Snyder Family’s Pending Sale of the Washington Commanders to Josh Harris and Partners
On May 12, 2023, the Washington Commanders and a partnership led by Josh Harris announced they have entered into a purchase and sale agreement which calls for Harris and partners to acquire the Washington Commanders from the Snyder family. The agreement is subject to NFL approval as well as the satisfaction of customary closing conditions. Cravath is representing the Snyder family in connection with the transaction.
Deals & Cases
September 12, 2023
WestRock’s $20 Billion Combination with Smurfit Kappa to Create Global Leader in Sustainable Packaging
On September 12, 2023, the Boards of WestRock and Smurfit Kappa announced the signing of a definitive transaction agreement to create Smurfit WestRock, a global leader in sustainable packaging. Together, Smurfit Kappa and WestRock generated combined last twelve months’ adjusted annual revenue of approximately $34 billion as of June 30, 2023. Cravath is representing WestRock in connection with the transaction.
Deals & Cases
October 11, 2022
Brookfield Renewable and Cameco’s $7.875 Billion Acquisition of Westinghouse
On October 11, 2022, Brookfield Renewable Partners (“Brookfield Renewable”), together with its institutional partners and Cameco Corporation (“Cameco”), announced they are forming a strategic partnership (“the consortium”) to acquire Westinghouse Electric Company (“Westinghouse”), one of the world’s largest nuclear services businesses, for a total enterprise value of $7.875 billion.
Deals & Cases
July 28, 2023
Biogen’s $7.3 Billion Acquisition of Reata Pharmaceuticals
On July 28, 2023, Biogen Inc. (“Biogen”) and Reata Pharmaceuticals, Inc. (“Reata”) announced that they have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Cravath is representing Biogen in connection with the transaction.
